Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis.

Slides:



Advertisements
Similar presentations
Verstovsek S et al. Proc ASCO 2011;Abstract 6500.
Advertisements

Ongoing clinical trials with JAK2 inhibitors in MF
Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA JAK.
Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA Therapy.
Results of a Randomized Study of the JAK Inhibitor Ruxolitinib (INC424) versus Best Available Therapy (BAT) in Primary Myelofibrosis (PMF), Post- Polycythemia.
Results of a Phase II Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, in Patients with Primary, Post-Polycythemia Vera, and Post- Essential.
Efficacy, Hematologic Effects and Dose of Ruxolitinib in Myelofibrosis Patients with Low Platelet Starting Counts ( x 10 9 /L): A Comparison to Patients.
Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study by David M.
Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,
Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.
Interim Results from a Phase 2, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation.
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.
Verstovsek S et al. Proc ASH 2011;Abstract 793.
Harrison CN et al. Proc ASH 2015;Abstract 59.
PERSIST-1: Pacritinib Improved Spleen Volume Reductions in Myelofibrosis vs Best Available Therapy CCO Independent Conference Highlights of the 2015 ASCO.
New Findings in Hematology: Independent Conference Coverage
Hypocholesterolemia Is Independently Associated with Decreased Survival in Patients with Primary Myelofibrosis: An Analysis of Lipid Profiles in 558 Myeloproliferative.
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
How Many Inhibitors for JAK2?
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL by Jennifer A. Woyach,
Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase.
A Randomized Trial Of Daily Prednisone Versus Pulsed Dexamethasone In Treatment Naïve Patients With Idiopathic Thrombocytopenic Purpura by Johannes Matschke,
Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib by Keyur P. Patel, Kate J. Newberry, Rajyalakshmi.
Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,
An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim.
Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning by Navneet S. Majhail, Ruta Brazauskas,
The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve.
An Unusual Cause of Abdominal Pain in Sickle Cell Disease
by John C. Wood, Pinggao Zhang, Hugh Y
by Alexander Röth, Andreas Hüttmann, Russell P
Vikas Gupta, Jason Gotlib, Jerald P. Radich, Nicolaus M
by Sabah Sallah, and Jim Y. Wan
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)‏ by Paolo Strati, Michael J. Keating,
Primary testicular lymphoma
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,
Allogeneic Stem Cell Transplantation in Myelofibrosis
Future Directions in Myelofibrosis: Implications of Emerging Approaches.
by John J. Strouse, Megan E. Reller, David G
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma by Pier Luigi Zinzani, Vincent.
Addressing Unmet Needs in Myelofibrosis
HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab.
1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.
Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.
Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I  Carole B. Miller, Rami S. Komrokji, Ruben A. Mesa,
Flow of Patients Through the Trial
Baseline Characteristics, Blood Pressures, and Laboratory Values
by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc
Patient Disposition James A. de Lemos et al. JAMA 2004; 292:
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms by Raajit K. Rampal, John O. Mascarenhas,
Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.
by Wendy Lim, Sara K. Vesely, and James N. George
Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry by Donald M. Arnold, Ishac Nazy, Rumi.
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia by Benjamin L. Lampson, Haesook T. Kim, Matthew.
Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study by Jeffrey.
Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Time-dependent survival estimation in post–polycythemia vera myelofibrosis.
Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.
by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio
Initial treatment of CLL: integrating biology and functional status
Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects
Is Skull-Base to Proximal Thigh PET/CT Enough
Cold agglutinin disease
Presentation transcript:

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis (MF) and Platelet Counts ≤100,000/µl by Srdan Verstovsek, James P. Dean, Paul Cernohous, Rami S Komrokji, John F. Seymour, Ruben A. Mesa, Mary S Campbell, Susan E. Caldwell, Lixia Wang, and Han Myint Blood Volume 122(21):395-395 November 15, 2013 ©2013 by American Society of Hematology

Spleen Response by MRI in All Patients. James P. Dean et al. Blood 2013;122:395 ©2013 by American Society of Hematology

≥35% REDUCTION IN SPLEEN VOLUME FROM BASELINE BY MRI (EVALUABLE POPULATION with MF). James P. Dean et al. Blood 2013;122:395 ©2013 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.